MX2023006732A - Composiciones y metodos de prolongacion de la vida media. - Google Patents
Composiciones y metodos de prolongacion de la vida media.Info
- Publication number
- MX2023006732A MX2023006732A MX2023006732A MX2023006732A MX2023006732A MX 2023006732 A MX2023006732 A MX 2023006732A MX 2023006732 A MX2023006732 A MX 2023006732A MX 2023006732 A MX2023006732 A MX 2023006732A MX 2023006732 A MX2023006732 A MX 2023006732A
- Authority
- MX
- Mexico
- Prior art keywords
- life extending
- methods
- antibody
- compositions
- extending compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Lubricants (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063122818P | 2020-12-08 | 2020-12-08 | |
| PCT/US2021/062238 WO2022125566A1 (en) | 2020-12-08 | 2021-12-07 | Half-life extending compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006732A true MX2023006732A (es) | 2023-08-14 |
Family
ID=81973740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006732A MX2023006732A (es) | 2020-12-08 | 2021-12-07 | Composiciones y metodos de prolongacion de la vida media. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240034814A1 (https=) |
| EP (1) | EP4259178A4 (https=) |
| JP (1) | JP2023552462A (https=) |
| KR (1) | KR20230156897A (https=) |
| CN (1) | CN117042788A (https=) |
| AU (1) | AU2021397734A1 (https=) |
| CA (1) | CA3201560A1 (https=) |
| MX (1) | MX2023006732A (https=) |
| WO (1) | WO2022125566A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1355919E (pt) * | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| WO2004041867A2 (en) * | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders |
| SG173488A1 (en) * | 2009-02-19 | 2011-09-29 | Glaxo Group Ltd | Improved anti-serum albumin binding variants |
| CN111433224B (zh) * | 2017-11-17 | 2024-03-19 | 南京传奇生物科技有限公司 | 抗pd-l1的单结构域抗体及其变体 |
| WO2019204925A1 (en) * | 2018-04-24 | 2019-10-31 | National Research Council Of Canada | Serum albumin binding antibodies for tuneable half-life extension of biologics |
| CN113508134B (zh) * | 2019-02-22 | 2024-12-03 | 安维达生物科技公司 | 白蛋白结合抗体及其用途 |
-
2021
- 2021-12-07 CN CN202180091880.6A patent/CN117042788A/zh active Pending
- 2021-12-07 US US18/256,276 patent/US20240034814A1/en active Pending
- 2021-12-07 KR KR1020237022999A patent/KR20230156897A/ko active Pending
- 2021-12-07 EP EP21904262.9A patent/EP4259178A4/en active Pending
- 2021-12-07 AU AU2021397734A patent/AU2021397734A1/en active Pending
- 2021-12-07 MX MX2023006732A patent/MX2023006732A/es unknown
- 2021-12-07 JP JP2023534636A patent/JP2023552462A/ja active Pending
- 2021-12-07 WO PCT/US2021/062238 patent/WO2022125566A1/en not_active Ceased
- 2021-12-07 CA CA3201560A patent/CA3201560A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023552462A (ja) | 2023-12-15 |
| EP4259178A4 (en) | 2024-10-30 |
| EP4259178A1 (en) | 2023-10-18 |
| CN117042788A (zh) | 2023-11-10 |
| AU2021397734A9 (en) | 2024-09-05 |
| AU2021397734A1 (en) | 2023-07-06 |
| CA3201560A1 (en) | 2022-06-16 |
| US20240034814A1 (en) | 2024-02-01 |
| WO2022125566A1 (en) | 2022-06-16 |
| KR20230156897A (ko) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023006732A (es) | Composiciones y metodos de prolongacion de la vida media. | |
| SA521422394B1 (ar) | Ccr8 جسم مضاد جديد لـ | |
| EP4592309A3 (en) | Heterotandem bicyclic peptide complexes | |
| MX2024008677A (es) | Conjugados de camptotecina. | |
| MX2021006681A (es) | Anticuerpos anti-claudina y usos de los mismos. | |
| EP4559323A3 (en) | Non-animal based protein sources with functional properties | |
| AU2019321490A8 (en) | Ox40-binding polypeptides and uses thereof | |
| WO2021236980A8 (en) | Coronavirus antigen compositions and their uses | |
| DE602005016773D1 (de) | Antikrebs-antikörper mit reduzierter komplementfixierung | |
| WO2019183359A8 (en) | Methods and compositions for molecular authentication | |
| MX2020008030A (es) | Anticuerpos de glipicano 3 y conjugados de los mismos. | |
| ZA202106602B (en) | Claudin 6 antibodies and uses thereof | |
| HRP20050354B1 (https=) | ||
| TW200738750A (en) | Ligands and methods of use therefor | |
| WO2020225805A3 (en) | Precursor tri-specific antibody constructs and methods of use thereof | |
| WO2021203016A3 (en) | Protein-protein interaction stabilizers | |
| PH12022550246A1 (en) | A dosing regimen for an ido inhibitor | |
| ZA202213434B (en) | Anti-lilrb1 antibody and uses thereof | |
| ZA202208280B (en) | Antibody molecules to c5ar1 and uses thereof | |
| DE602004027992D1 (de) | In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135 | |
| MX2022011077A (es) | Variantes de transglutaminasa. | |
| NO20075140L (no) | Fremgangsmater og preparater for modulering av vaskulaer integritet | |
| MX2007005202A (es) | Polisacaridos de estreptococo modificados y usos de los mismos. | |
| WO2006134190A3 (es) | Agentes y métodos basados en el uso del dominio eda de la fibronectina | |
| ATE469177T1 (de) | Bauadditive auf basis von gereinigtem hydrophobisch modifiziertem hydroxyalkyl guar |